APPLAUSE-IgAN is a Phase 3 global clinical trial that will look at the effects of an investigational drug, iptacopan (LNP023), in people with IgAN. The trial will study the effects of iptacopan (LNP023) on reducing inflammation and kidney damage in people with IgAN.
Introducing the APPLAUSE-IgAN trial
For participants, the trial will last a little over two years in total. This includes a screening visit and run-in period of up to three months to see if they qualify (participants will not be given the investigational drug during this time), followed by a treatment period of two years.